Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial

Open access

Abstract

Pancreatic and colorectal cancers are often KRAS mutated and are incurable when tumor DNA or protein persists or recurs after curative intent therapy. Cancer vaccine ELI-002 2P enhances lymph node delivery and immune response using amphiphile (Amph) modification of G12D and G12R mutant KRAS (mKRAS) peptides (Amph-Peptides-2P) together with CpG oligonucleotide adjuvant (Amph-CpG-7909). We treated 25 patients (20 pancreatic and five colorectal) who were positive for minimal residual mKRAS disease (ctDNA and/or serum tumor antigen) after locoregional treatment in a phase 1 study of fixed-dose Amph-Peptides-2P and ascending-dose Amph-CpG-7909; study enrollment is complete with patient follow-up ongoing. Primary endpoints included safety and recommended phase 2 dose (RP2D). The secondary endpoint was tumor biomarker response (longitudinal ctDNA or tumor antigen), with exploratory endpoints including immunogenicity and relapse-free survival (RFS). No dose-limiting toxicities were observed, and the RP2D was 10.0 mg of Amph-CpG-7909. Direct ex vivo mKRAS-specific T cell responses were observed in 21 of 25 patients (84%; 59% both CD4 + and CD8 + ); tumor biomarker responses were observed in 21 of 25 patients (84%); biomarker clearance was observed in six of 25 patients (24%; three pancreatic and three colorectal); and the median RFS was 16.33 months. Efficacy correlated with T cell responses above or below the median fold increase over baseline (12.75-fold): median tumor biomarker reduction was −76.0% versus −10.2% ( P < 0.0014), and the median RFS was not reached versus 4.01 months (hazard ratio = 0.14; P = 0.0167). ELI-002 2P was safe and induced considerable T cell responses in patients with immunotherapy-recalcitrant KRAS-mutated tumors. ClinicalTrials.gov identifier: NCT04853017 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02760-3

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Design of ELI-002 2P, Amph mechanism of action and study participant disposition. a, Schematic for ELI-002 2P vaccine components, including Amph-mKRAS G12D and G12R long peptide antigens and Amph-CpG-7909 TLR9 agonist. PEG, polyethylene glycol. b, Stepwise schematic for Amph-directed lymph-node-targeted biodistribution mechanism using albumin ‘hitchhiking’: (1) subcutaneous Amph injection, followed by (2) lipid-mediated non-covalent molecular association of Amph vaccines with tissue-resident endogenous albumin, resulting in (3) preferential absorption into lymphatics and accumulation through afferent lymph flow into draining lymph nodes and, finally, (4) uptake of Amph vaccines by lymph-node-resident APCs to induce antigen presentation and coordinated co-stimulation of cognate T cells. c, CONSORT diagram. Patients were enrolled into five successive cohorts with progressively increasing doses of Amph-CpG-7909 with a fixed dose of Amph-Peptides 2P. Graphical elements from a and b were adapted from previous publications under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/) (refs. 57,58).
Fig. 1 Design of ELI-002 2P, Amph mechanism of action and study participant disposition. a, Schematic for ELI-002 2P vaccine components, including Amph-mKRAS G12D and G12R long peptide antigens and Amph-CpG-7909 TLR9 agonist. PEG, polyethylene glycol. b, Stepwise schematic for Amph-directed lymph-node-targeted biodistribution mechanism using albumin ‘hitchhiking’: (1) subcutaneous Amph injection, followed by (2) lipid-mediated non-covalent molecular association of Amph vaccines with tissue-resident endogenous albumin, resulting in (3) preferential absorption into lymphatics and accumulation through afferent lymph flow into draining lymph nodes and, finally, (4) uptake of Amph vaccines by lymph-node-resident APCs to induce antigen presentation and coordinated co-stimulation of cognate T cells. c, CONSORT diagram. Patients were enrolled into five successive cohorts with progressively increasing doses of Amph-CpG-7909 with a fixed dose of Amph-Peptides 2P. Graphical elements from a and b were adapted from previous publications under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/) (refs. 57,58).CC BY · PubMed Central
Fig. 2 ELI-002 2P treatment results in tumor biomarker reduction and clearance. a, Best overall tumor biomarker response for study participants reported as percentage of the baseline value. Responses are annotated for patient number, dose cohort, participant tumor type, KRAS mutation, tumor biomarker type and presence or absence of previously reported mKRAS-responsive HLA class I and II. * Patient 16 underwent excisional biopsy to assess iRECIST, and T cell infiltrate was observed; a contribution to ctDNA clearance could not be ruled out. ‘S’ indicates that the patient underwent splenectomy. b, Swimmer plot supervised by T cell response (maximum fold change from baseline; top: ≥median; bottom: <median) showing time from surgery to start of ELI-002 2P (left) and time from start of ELI-002 2P to endpoint (right; data cutoff or death), n = 25. Bar color indicates best overall tumor biomarker response for each patient. Symbols annotate the timing of completion of prime and boost immunizations, the start of subsequent therapy, iCPD, the most recent date of censor for RFS (the date of the most recent radiographic scan before the date of subsequent therapy, the data cutoff or the date of death) and the date of death where applicable. Arrows indicate ongoing treatment or ongoing follow-up. iCPD, immune confirmed progressive disease.
Fig. 2 ELI-002 2P treatment results in tumor biomarker reduction and clearance. a, Best overall tumor biomarker response for study participants reported as percentage of the baseline value. Responses are annotated for patient number, dose cohort, participant tumor type, KRAS mutation, tumor biomarker type and presence or absence of previously reported mKRAS-responsive HLA class I and II. * Patient 16 underwent excisional biopsy to assess iRECIST, and T cell infiltrate was observed; a contribution to ctDNA clearance could not be ruled out. ‘S’ indicates that the patient underwent splenectomy. b, Swimmer plot supervised by T cell response (maximum fold change from baseline; top: ≥median; bottom: <median) showing time from surgery to start of ELI-002 2P (left) and time from start of ELI-002 2P to endpoint (right; data cutoff or death), n = 25. Bar color indicates best overall tumor biomarker response for each patient. Symbols annotate the timing of completion of prime and boost immunizations, the start of subsequent therapy, iCPD, the most recent date of censor for RFS (the date of the most recent radiographic scan before the date of subsequent therapy, the data cutoff or the date of death) and the date of death where applicable. Arrows indicate ongoing treatment or ongoing follow-up. iCPD, immune confirmed progressive disease.CC BY · PubMed Central
Fig. 3 Robust direct ex vivo mKRAS-specific T cell responses induced by ELI-002 2P in a majority of patients. Patients were immunized with 1.4 mg of Amph-Peptides 2P admixed with 0.1, 0.5, 2.5, 5 or 10 mg of Amph-CpG-7909. PBMCs were collected for T cell response assessment at baseline and post-immunization timepoints. a, Shown is the fold change from baseline to maximum response in the ex vivo FluoroSpot assay or ICS assay for T cell responders (n = 21/25 patients). T cell responders are defined as patients having a ≥2-fold increase from baseline at any post-vaccination timepoint (dotted line) and >50 SFCs/1 × 106 PBMCs for FluoroSpot assay or >0.1% cytokine-positive for ICS assay. The median fold change is shown at 12.75, indicated by a dashed line. * Patients without baseline-detectable T cell responses (below the response threshold) had on-treatment fold change of 348×, 58.3×, 20.7×, 18.3×, 9.7×, 3.7× and 2.1×. b, Pie chart shows the percentage of T cell responders and non-responders to ex vivo FluoroSpot and ICS. c, Table shows the percentage of T cell responders to ex vivo FluoroSpot and ICS and average fold change of T cell responders per dose cohort. d, Pie chart depicts the percentage of T cell responders that induce CD4+, CD8+ or both CD4+ and CD8+ cytokine-positive cells in ICS assay. e, Pie chart indicates the percentage of T cell responders that induce T cell responses to 1, 2–4, 5–6 or all 7 assessed mKRAS antigens. f, Pie chart shows the percentage of T cell responders that induce T cell responses to immunizing antigens G12D and/or G12R. g, Bar graph indicates the number of mKRAS antigens that induced T cell responses after vaccination for each patient, n = 25. h, CD3 immunohistochemical analysis of hepatic tumor biopsy tissue section collected from patient 2 after observation of a contrast avid lesion by computed tomography (CT) 33 d after the start of treatment. Twenty-four CD3+ T cells per high-powered field (×400) were quantitated by the study pathologist in the region of highest labeling. i, CD3 immunohistochemical analysis of hepatic tumor biopsy tissue section collected from patient 18 after observation of a contrast avid lesion by CT. Seventy-six CD3+ T cells per high-powered field (×400) were quantitated by the study pathologist in the region of highest labeling. Pt., patient.
Fig. 3 Robust direct ex vivo mKRAS-specific T cell responses induced by ELI-002 2P in a majority of patients. Patients were immunized with 1.4 mg of Amph-Peptides 2P admixed with 0.1, 0.5, 2.5, 5 or 10 mg of Amph-CpG-7909. PBMCs were collected for T cell response assessment at baseline and post-immunization timepoints. a, Shown is the fold change from baseline to maximum response in the ex vivo FluoroSpot assay or ICS assay for T cell responders (n = 21/25 patients). T cell responders are defined as patients having a ≥2-fold increase from baseline at any post-vaccination timepoint (dotted line) and >50 SFCs/1 × 106 PBMCs for FluoroSpot assay or >0.1% cytokine-positive for ICS assay. The median fold change is shown at 12.75, indicated by a dashed line. * Patients without baseline-detectable T cell responses (below the response threshold) had on-treatment fold change of 348×, 58.3×, 20.7×, 18.3×, 9.7×, 3.7× and 2.1×. b, Pie chart shows the percentage of T cell responders and non-responders to ex vivo FluoroSpot and ICS. c, Table shows the percentage of T cell responders to ex vivo FluoroSpot and ICS and average fold change of T cell responders per dose cohort. d, Pie chart depicts the percentage of T cell responders that induce CD4+, CD8+ or both CD4+ and CD8+ cytokine-positive cells in ICS assay. e, Pie chart indicates the percentage of T cell responders that induce T cell responses to 1, 2–4, 5–6 or all 7 assessed mKRAS antigens. f, Pie chart shows the percentage of T cell responders that induce T cell responses to immunizing antigens G12D and/or G12R. g, Bar graph indicates the number of mKRAS antigens that induced T cell responses after vaccination for each patient, n = 25. h, CD3 immunohistochemical analysis of hepatic tumor biopsy tissue section collected from patient 2 after observation of a contrast avid lesion by computed tomography (CT) 33 d after the start of treatment. Twenty-four CD3+ T cells per high-powered field (×400) were quantitated by the study pathologist in the region of highest labeling. i, CD3 immunohistochemical analysis of hepatic tumor biopsy tissue section collected from patient 18 after observation of a contrast avid lesion by CT. Seventy-six CD3+ T cells per high-powered field (×400) were quantitated by the study pathologist in the region of highest labeling. Pt., patient.CC BY · PubMed Central
Fig. 4 mKRAS T cell response correlates to tumor biomarker response and delayed tumor recurrence. a, OS from study start (date of first vaccine dose), n = 25; n indicates individual patients. b, Best overall tumor biomarker response for study participants reported as percentage of the baseline value, stratified by T cell response (maximum fold change from baseline; ≥ median versus < median), n = 25. P value was calculated by two-tailed Mann–Whitney test. c, RFS from study start (date of first vaccine dose), n = 25; n indicates individual patients. Values depicted are mean ± s.d. d, RFS from study start (date of first vaccine dose) stratified by T cell response (maximum fold change from baseline; ≥median versus <median), n = 25; n indicates individual patients. HR indicates hazard ratio with 95% CI. P values were calculated using two-tailed log-rank test.
Fig. 4 mKRAS T cell response correlates to tumor biomarker response and delayed tumor recurrence. a, OS from study start (date of first vaccine dose), n = 25; n indicates individual patients. b, Best overall tumor biomarker response for study participants reported as percentage of the baseline value, stratified by T cell response (maximum fold change from baseline; ≥ median versus < median), n = 25. P value was calculated by two-tailed Mann–Whitney test. c, RFS from study start (date of first vaccine dose), n = 25; n indicates individual patients. Values depicted are mean ± s.d. d, RFS from study start (date of first vaccine dose) stratified by T cell response (maximum fold change from baseline; ≥median versus <median), n = 25; n indicates individual patients. HR indicates hazard ratio with 95% CI. P values were calculated using two-tailed log-rank test.CC BY · PubMed Central
Extended Data Fig. 1 Study schema. Treatment with ELI-002 2P was conducted in a priming immunization period (B: baseline – week 7) and subsequent boosting immunization period (week 20-23) for CRC or PDAC patients exhibiting tumor expression of mKRAS G12D or G12R following completion of locoregional therapy, radiological confirmation of no evidence of disease, and detection of either ctDNA or serum tumor biomarker indicating positivity for minimal residual disease (MRD).
Extended Data Fig. 1 Study schema. Treatment with ELI-002 2P was conducted in a priming immunization period (B: baseline – week 7) and subsequent boosting immunization period (week 20-23) for CRC or PDAC patients exhibiting tumor expression of mKRAS G12D or G12R following completion of locoregional therapy, radiological confirmation of no evidence of disease, and detection of either ctDNA or serum tumor biomarker indicating positivity for minimal residual disease (MRD).CC BY · PubMed Central
Extended Data Fig. 2 ELI-002 2P treatment results in tumor biomarker reduction and clearance. Longitudinal changes in biomarker levels as a percentage of baseline values for each evaluable patient, n = 25. Responses are annotated based on the best overall biomarker response observed for each patient during the course of study.
Extended Data Fig. 2 ELI-002 2P treatment results in tumor biomarker reduction and clearance. Longitudinal changes in biomarker levels as a percentage of baseline values for each evaluable patient, n = 25. Responses are annotated based on the best overall biomarker response observed for each patient during the course of study.CC BY · PubMed Central
Extended Data Fig. 3 Robust direct ex vivo mKRAS-specific T cell responses induced by ELI-002 2P in a majority of patients. Patients were immunized with 1.4 mg Amph-Peptides 2P admixed with 0.1, 0.5, 2.5, 5 or 10 mg of Amph-CpG-7909. PBMCs were collected for T cell response assessment at baseline and post-immunization timepoints. a, PBMCs were stimulated with OLPs to all 7 mKRAS antigens in the IFNγ/GrB Fluorospot assay for 44 hours. Shown are background-subtracted IFNγ and/or GrB SFCs per 1 × 106 PBMCs for the maximum response for each patient. T cell responders are defined as a patients having ≥2-fold increase from baseline at any post-vaccination timepoint and >50 SFC/1×106 PBMCs (dotted line). b, PBMCs were stimulated with all 7 mKRAS OLPs prior to analysis for intracellular cytokines, IFNγ, TNFa and IL-2 by flow cytometry. Shown are frequencies of the maximum cytokine producing CD4+ or CD8+ T cells for each patient. T cell responders are defined as a patients having ≥2-fold increase from baseline at any post-vaccination timepoint and > 0.1% cytokine+ (dotted line). c, Pie chart shows the percentage of T cell responders that induce T cell responses to non-immunizing antigens (G12V, G12C, G12A, G12S, G13D). d, Pie chart depicts the percentage of T cell responders exhibiting pre-existing mKRAS-specific T cells seen at baseline before ELI-002 2P vaccination, n = 21. e, PBMCs were stimulated with OLPs to all 7 mKRAS antigens in the IFNγ/GrB Fluorospot assay for 44 hours. Shown are background-subtracted IFNγ and/or GrB SFCs per 1 × 106 PBMCs for the 7 patients with post-booster vaccination timepoints. The arrows on the graph indicate the prime and boost vaccinations; dotted line indicates 50 SFC/1 x 106 PBMCs.
Extended Data Fig. 3 Robust direct ex vivo mKRAS-specific T cell responses induced by ELI-002 2P in a majority of patients. Patients were immunized with 1.4 mg Amph-Peptides 2P admixed with 0.1, 0.5, 2.5, 5 or 10 mg of Amph-CpG-7909. PBMCs were collected for T cell response assessment at baseline and post-immunization timepoints. a, PBMCs were stimulated with OLPs to all 7 mKRAS antigens in the IFNγ/GrB Fluorospot assay for 44 hours. Shown are background-subtracted IFNγ and/or GrB SFCs per 1 × 106 PBMCs for the maximum response for each patient. T cell responders are defined as a patients having ≥2-fold increase from baseline at any post-vaccination timepoint and >50 SFC/1×106 PBMCs (dotted line). b, PBMCs were stimulated with all 7 mKRAS OLPs prior to analysis for intracellular cytokines, IFNγ, TNFa and IL-2 by flow cytometry. Shown are frequencies of the maximum cytokine producing CD4+ or CD8+ T cells for each patient. T cell responders are defined as a patients having ≥2-fold increase from baseline at any post-vaccination timepoint and > 0.1% cytokine+ (dotted line). c, Pie chart shows the percentage of T cell responders that induce T cell responses to non-immunizing antigens (G12V, G12C, G12A, G12S, G13D). d, Pie chart depicts the percentage of T cell responders exhibiting pre-existing mKRAS-specific T cells seen at baseline before ELI-002 2P vaccination, n = 21. e, PBMCs were stimulated with OLPs to all 7 mKRAS antigens in the IFNγ/GrB Fluorospot assay for 44 hours. Shown are background-subtracted IFNγ and/or GrB SFCs per 1 × 106 PBMCs for the 7 patients with post-booster vaccination timepoints. The arrows on the graph indicate the prime and boost vaccinations; dotted line indicates 50 SFC/1 x 106 PBMCs.CC BY · PubMed Central
Extended Data Fig. 4 ELI-002 2P immunization induces robust T cell responses to mKRAS antigens. Patient 11 was immunized with 1.4 mg Amph-Peptides 2P admixed with 5 mg of Amph-CpG-7909. PBMCs were collected for ex vivo T cell response assessments at baseline (B) and week 9. a, Schema showing dosing and experimental schedule. PBMCs were stimulated with OLPs to b, G12D or G12R, c, G12V, G12C, G12A, G12S or G13D or d, WT KRAS in the same IFNγ/GrB Fluorospot assay for 44 hours. Shown are background-subtracted IFNγ and/or GrB SFCs per 1 × 106 PBMCs; dotted line indicates 50 SFC/1 x 106 PBMCs. The pie charts in b, c show the percentage of mKRAS OLP-stimulated PBMCs at week 9 secreting IFNγ, GrB or both IFNγ and GrB. e, f, PBMCs were stimulated with G12R or G12D OLPs prior to analysis for intracellular cytokines, IFNγ, TNFa and IL-2 by flow cytometry. Shown are frequencies of total IL2, TNFα, IFNγ polyfunctional cytokine producing e, CD4+ and f, CD8+ T cells. The pie charts in e, f show the percentage of G12R and G12D stimulated PBMCs producing IFNγ, IL2, TNFα, producing 2 cytokines (2+) or producing 3 cytokines (3+) at week 9. g, The pie charts depict the percentage of G12R-stimulated memory CD4+ and CD8+ T cells in cytokine negative and cytokine positive cells at week 9 (Naïve: CCR7+ CD45RA+, Central memory: CCR7 + CD45RA-, Effector memory: CCR7- CD45RA-, Terminal effector memory: CCR7- CD45RA+).
Extended Data Fig. 4 ELI-002 2P immunization induces robust T cell responses to mKRAS antigens. Patient 11 was immunized with 1.4 mg Amph-Peptides 2P admixed with 5 mg of Amph-CpG-7909. PBMCs were collected for ex vivo T cell response assessments at baseline (B) and week 9. a, Schema showing dosing and experimental schedule. PBMCs were stimulated with OLPs to b, G12D or G12R, c, G12V, G12C, G12A, G12S or G13D or d, WT KRAS in the same IFNγ/GrB Fluorospot assay for 44 hours. Shown are background-subtracted IFNγ and/or GrB SFCs per 1 × 106 PBMCs; dotted line indicates 50 SFC/1 x 106 PBMCs. The pie charts in b, c show the percentage of mKRAS OLP-stimulated PBMCs at week 9 secreting IFNγ, GrB or both IFNγ and GrB. e, f, PBMCs were stimulated with G12R or G12D OLPs prior to analysis for intracellular cytokines, IFNγ, TNFa and IL-2 by flow cytometry. Shown are frequencies of total IL2, TNFα, IFNγ polyfunctional cytokine producing e, CD4+ and f, CD8+ T cells. The pie charts in e, f show the percentage of G12R and G12D stimulated PBMCs producing IFNγ, IL2, TNFα, producing 2 cytokines (2+) or producing 3 cytokines (3+) at week 9. g, The pie charts depict the percentage of G12R-stimulated memory CD4+ and CD8+ T cells in cytokine negative and cytokine positive cells at week 9 (Naïve: CCR7+ CD45RA+, Central memory: CCR7 + CD45RA-, Effector memory: CCR7- CD45RA-, Terminal effector memory: CCR7- CD45RA+).CC BY · PubMed Central
Extended Data Fig. 5 ELI-002 immunization induces robust T cell responses to mKRAS antigens. Patient 23 was immunized with 1.4 mg Amph-Peptides 2P admixed with 10 mg of Amph-CpG-7909. PBMCs were collected for ex vivo T cell response assessments at baseline (B) and Week 9. a, Schema showing dosing and experimental schedule. PBMCs were stimulated with OLPs to b, G12D or G12R, c, G12V, G12C, G12A, G12S or G13D or d, WT KRAS in the same IFNγ/GrB Fluorospot assay for 44 hours; dotted line indicates 50 SFC/1 x 106 PBMCs. Shown are background-subtracted IFNγ and/or GrB SFCs per 1 × 106 PBMCs. The pie charts in b, c show the percentage of mKRAS OLP-stimulated PBMCs at week 9 secreting IFNγ, GrB or both IFNγ and GrB. e, f, PBMCs were stimulated with G12R or G12D OLPs prior to analysis for intracellular cytokines, IFNγ, TNFa and IL-2 by flow cytometry. Shown are frequencies of total IL2, TNFα, IFNγ polyfunctional cytokine producing e, CD4+ and f, CD8+ T cells. The pie charts in e, f show the percentage of G12R and G12D stimulated PBMCs producing IFNγ, IL2, TNFα, producing 2 cytokines (2+) or producing 3 cytokines (3+) at week 9. g, The pie charts depict the percentage of G12R-stimulated memory CD4+ and CD8+ T cells in cytokine negative and cytokine positive cells at week 9 (Naïve: CCR7 + CD45RA+, Central memory: CCR7 + CD45RA-, Effector memory: CCR7- CD45RA-, Terminal effector memory: CCR7- CD45RA+).
Extended Data Fig. 5 ELI-002 immunization induces robust T cell responses to mKRAS antigens. Patient 23 was immunized with 1.4 mg Amph-Peptides 2P admixed with 10 mg of Amph-CpG-7909. PBMCs were collected for ex vivo T cell response assessments at baseline (B) and Week 9. a, Schema showing dosing and experimental schedule. PBMCs were stimulated with OLPs to b, G12D or G12R, c, G12V, G12C, G12A, G12S or G13D or d, WT KRAS in the same IFNγ/GrB Fluorospot assay for 44 hours; dotted line indicates 50 SFC/1 x 106 PBMCs. Shown are background-subtracted IFNγ and/or GrB SFCs per 1 × 106 PBMCs. The pie charts in b, c show the percentage of mKRAS OLP-stimulated PBMCs at week 9 secreting IFNγ, GrB or both IFNγ and GrB. e, f, PBMCs were stimulated with G12R or G12D OLPs prior to analysis for intracellular cytokines, IFNγ, TNFa and IL-2 by flow cytometry. Shown are frequencies of total IL2, TNFα, IFNγ polyfunctional cytokine producing e, CD4+ and f, CD8+ T cells. The pie charts in e, f show the percentage of G12R and G12D stimulated PBMCs producing IFNγ, IL2, TNFα, producing 2 cytokines (2+) or producing 3 cytokines (3+) at week 9. g, The pie charts depict the percentage of G12R-stimulated memory CD4+ and CD8+ T cells in cytokine negative and cytokine positive cells at week 9 (Naïve: CCR7 + CD45RA+, Central memory: CCR7 + CD45RA-, Effector memory: CCR7- CD45RA-, Terminal effector memory: CCR7- CD45RA+).CC BY · PubMed Central
Extended Data Fig. 6 Baseline prognostic values and landmark RFS analysis. a-e, RFS from study start (date of first vaccine dose) stratified by a, tumor stage at baseline, n = 25, b, absolute lymphocyte count in peripheral blood at baseline, n = 25, c, absolute neutrophil count in peripheral blood at baseline, n = 25, d, %CD4+ among CD3+ lymphocytes at baseline among ICS evaluable patients, n = 22, e, %CD8+ among CD3+ lymphocytes at baseline among ICS evaluable patients, n = 22. f, RFS from landmark (completion of prime immunization) stratified by T cell response (Maximum fold change from baseline; ≥ Median versus < Median) among evaluable patients with RFS exceeding the landmark as of the data cut-off, n = 22. n indicates individual patients. HR indicates hazard ratio with 95% CI. P values calculated using two-tailed log-rank test.
Extended Data Fig. 6 Baseline prognostic values and landmark RFS analysis. a-e, RFS from study start (date of first vaccine dose) stratified by a, tumor stage at baseline, n = 25, b, absolute lymphocyte count in peripheral blood at baseline, n = 25, c, absolute neutrophil count in peripheral blood at baseline, n = 25, d, %CD4+ among CD3+ lymphocytes at baseline among ICS evaluable patients, n = 22, e, %CD8+ among CD3+ lymphocytes at baseline among ICS evaluable patients, n = 22. f, RFS from landmark (completion of prime immunization) stratified by T cell response (Maximum fold change from baseline; ≥ Median versus < Median) among evaluable patients with RFS exceeding the landmark as of the data cut-off, n = 22. n indicates individual patients. HR indicates hazard ratio with 95% CI. P values calculated using two-tailed log-rank test.CC BY · PubMed Central
Extended Data Fig. 7 T cell response to infectious disease epitopes does not correlate to tumor biomarker response or delayed tumor recurrence. a, Best overall biomarker response for study participants reported as percentage of the baseline value, stratified by infectious disease epitope-specific T cell response (≥Median versus < Median), n = 23. Values depicted are mean ± standard deviation. P value calculated by two-tailed Mann-Whitney test. b, RFS from study start (date of first vaccine dose) stratified by infectious disease epitope-specific T cell response (≥Median versus < Median), n = 23. n indicates individual patients. HR indicates hazard ratio with 95% CI. P value calculated using two-tailed log-rank test.
Extended Data Fig. 7 T cell response to infectious disease epitopes does not correlate to tumor biomarker response or delayed tumor recurrence. a, Best overall biomarker response for study participants reported as percentage of the baseline value, stratified by infectious disease epitope-specific T cell response (≥Median versus < Median), n = 23. Values depicted are mean ± standard deviation. P value calculated by two-tailed Mann-Whitney test. b, RFS from study start (date of first vaccine dose) stratified by infectious disease epitope-specific T cell response (≥Median versus < Median), n = 23. n indicates individual patients. HR indicates hazard ratio with 95% CI. P value calculated using two-tailed log-rank test.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Cited by

See all 286

Metadata

Authors
Pant, S., Wainberg, Z. A., Weekes, C. D., Furqan, M., Kasi, P. M., Devoe, C. E., Leal, A. D., Chung, V., Basturk, O., VanWyk, H., Tavares, A. M., Seenappa, L. M., Perry, J. R., Kheoh, T., McNeil, L. K., Welkowsky, E., DeMuth, P. C., Haqq, C. M., & O’Reilly, E. M.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • University of California, Los Angeles (US)
  • Massachusetts General Hospital (US)
  • University of Iowa (US)
  • Northwell Health (US)
  • University of Colorado Anschutz (US)
  • City Of Hope National Medical Center (US)
Corresponding author
  • Pant, Shubham
  • Haqq, Christopher M.
Venue
Nature Medicine
Published
2024-01-09
Volume
30
Issue
2
Pages
531-542
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4390707107
Cited by
267
References
60
Citations by year
2026: 96 · 2025: 114 · 2024: 57
FWCI
44.65
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
Elicio Therapeutics
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
pancreatic cancer, colorectal cancer, minimal residual disease, circulating tumor DNA, T cell response, relapse-free survival, immunotherapy resistance, lymph node targeting
MeSH terms
Antigens, Neoplasm, Humans, Neoplasm Recurrence, Local, Peptides, Biomarkers, Tumor, Vaccines, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. https://app.cochat.ai/papers/10.1038/s41591-023-02760-3
The paper
Pant, S., Wainberg, Z. A., Weekes, C. D., Furqan, M., Kasi, P. M., Devoe, C. E., Leal, A. D., Chung, V., Basturk, O., VanWyk, H., Tavares, A. M., Seenappa, L. M., Perry, J. R., Kheoh, T., McNeil, L. K., Welkowsky, E., DeMuth, P. C., Haqq, C. M., & O’Reilly, E. M. (2024). Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02760-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.